Dsm-firmenich posts Q3 results slightly above expectations, raises growth outlook

Impact · against what's priced in

Dsm-firmenich is likely to see a moderate price increase following a slight Q3 beat and an upward revision of its growth outlook. The guidance raise serves as a concrete catalyst for analysts to revise FY2026 EPS estimates upward.

DSFIR+0.60

No priced-in read yet

In context

The company reported Q3 results slightly above expectations and raised its overall growth outlook, providing a positive catalyst for earnings estimates.

Read from the article alone

• earnings
• guidance
• DSFIR
• chemicals
• flavors
• fragrance
• growth outlook

Search tags